<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Arbidol is a non-nucleoside broad-spectrum antiviral drug for upper respiratory tract infections caused by influenza A and B viruses, and it was first approved in Russia [
 <xref ref-type="bibr" rid="CR43">43</xref>]. It can inhibit the adhesion of viruses to host cells and prevent them from invading human cells [
 <xref ref-type="bibr" rid="CR44">44</xref>]. At the same time, it can promote the synthesis of interferon, which can prevent influenza virus invasion and treat influenza virus infection [
 <xref ref-type="bibr" rid="CR45">45</xref>]. Some studies have confirmed that arbidol has a good effect against SARS-CoV and MERS-CoV infections [
 <xref ref-type="bibr" rid="CR46">46</xref>, 
 <xref ref-type="bibr" rid="CR47">47</xref>]. Chinese scientists found in in vitro cell experiments that compared with a drug-untreated control group, 10–30 μM arbidol can effectively inhibit SARS-CoV-2 up to 60 times and significantly inhibit the pathological effects of the virus on cells [
 <xref ref-type="bibr" rid="CR48">48</xref>]. As described in the latest “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia”, arbidol is used at a dose of 200 mg for adults three times daily, and the course of treatment does not exceed 10 days [
 <xref ref-type="bibr" rid="CR13">13</xref>]. It has been reported that some patients have improved symptoms after receiving arbidol [
 <xref ref-type="bibr" rid="CR49">49</xref>].
</p>
